Drug pipeline 2016
B 5, 4455 (2017).CrossRefGoogle Scholar Mondragn, L., Mas, N., Ferragud, V., de la Torre, C., Agostini, A., Martnez-Mez, R., Sancenn, F., Amors, P., Prez-Pay, E., and Orzez, M.: Enzyme-responsive intracellular-controlled release using silica mesoporous nanoparticles capped with -poly-L-lysine
The most common side effects are gastrointestinal: nausea (28%), diarrhea (24%), constipation (21%), and vomiting (17%) at the 12mg dose
For patients facing gaps in insurance coverage for specific medications, self-pay options and manufacturer savings programs are available
Distrofia muscular , padecimiento gentico que provoca prdida de masa muscular y debilidad
The primary time point for each trial was used as the endpoint